MERZ-PHARMA-GMBH

4.4.2019 10:21:09 CEST | Business Wire | Press release

Merz to Present New Aesthetics Clinical Data at AMWC 2019

Merz, a global leader in aesthetics and neurotoxins, announced today that clinical data on the use of the Merz Aesthetics portfolio, including Belotero^® , Cellfina^® , Radiesse^® , Ultherapy^® and Botulinum Toxin will be featured in oral and poster presentations at the 2019 Aesthetic & Anti-Aging Medicine World Congress (AMWC), to be held from Thursday, April 4 to Saturday, April 6, 2019 in Monte-Carlo, Monaco.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190404005258/en/

In addition to the poster presentations listed below, Merz Aesthetics is also sponsoring the Symposium event Early Intervention Meets Beautification – Treating the Social Media Generation, to be held on Friday, April 5 at 14.00h – 16.00h, Auditorium Prince Pierre . The session will include live injections and treatment insights from five international expert speakers:

Dr. Rolf Bartsch – Plastic Surgeon, Austria
Dr. Sabrina Fabi – Dermatologist, USA
Prof. Dr. Martina Kerscher – Dermatologist, Germany
Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
Dr. Sonja Sattler – Dermatologist, Germany
Marie Doppelhofer – Blogger and entrepreneur, Austria

Oral Presentations

Restorative properties of hydroxylapatite (Regenerative Aesthetics Session). Kate Goldie, MBChB – European Medical Aesthetics Ltd, London, UK; Sabrina Fabi, MD, Cosmetic Laser Dermatology, San Diego, USA. Thursday, April 4, 10:00-12:00h, Auditorium Camille Blanc
Elements of the face attractiveness and balance (Fillers: Natural Results and Attractiveness Session). Dr. Jani van Loghem, MD – Falck Clinic, Amsterdam, The Netherlands. Thursday, April 4, 14:00-16:00h, Auditorium Prince Pierre
Study with controlled subcision, calcium hydroxylapatite and microfocused ultrasound with visualization: What is the best algorithm for combination to improve cellulite appearance (Rubbish and Reality on Combined Treatments Session). Gabriela Casabona, MD – Ocean Clinic, Marbella. Saturday, April 6, 9:00-10:30h, Auditorium Camille Blanc

Poster Presentations

Posters will be available for viewing at the Poster Zone on Level 2, outside of the Camille Blanc Auditorium, from Thursday, April 4 to Saturday, April 6.

Botulinum Toxin

IncobotulinumtoxinA: A unique and pure formulation of botulinum neurotoxin type A for use in aesthetic and therapeutic medicine. Ada Trindade de Almeida, MD – Hospital do Servidor Municipal de São Paulo, São Paulo, Brazil.
Comparison of incobotulinumtoxinA to botulinum neurotoxin type A formulations in Asia. Jürgen Frevert, PhD – Formerly of Merz Pharmaceuticals GmbH, Frankfurt, Germany.
Escalating doses of incobotulinumtoxinA for extended treatment of glabellar frown lines: safety and efficacy results from a randomized, double-blind study. Corey Maas, MD – The Maas Clinic, San Francisco, CA, US.
Safety, tolerability, and efficacy of repeat-dose injections of incobotulinumtoxinA in the treatment of upper facial lines: results from a prospective, open-label, phase III study. Tanja Fischer, MD – Haut- & Lasercentrum, Potsdam, Germany.
Combined post-operative scar treatment with incobotulinumtoxinA and microneedling to improve the appearance and functionality of scarring following surgical removal of facial skin tumors and flap reconstruction. Gabriela Casabona, MD – Ocean Clinic, Marbella, Spain
Decrease in therapeutic effect among botulinum toxin type A agents: Analysis of the FDA adverse event reporting system database. Rashid Kazerooni, PharmD, MS, BCPS – Merz North America, Raleigh, NC, US

Belotero ^®

Open label multicenter post-market clinical follow-up to confirm the performance and the safety of CPM^® -HA20 in facial skin revitalization. Martina Kerscher, MD, PhD – University of Hamburg, Hamburg, Germany.
Cohesive polydensified matrix crosslinked hyaluronic acid volumizing gel: An MRI and CT study. Patrick Micheels, MD – Private Practice, Geneva, Switzerland

Radiesse ^®

Diluted and Hyperdiluted Calcium Hydroxylapatite for Skin Tightening: Guidelines from a Global Consensus Panel. Kate Goldie, MBChB – European Medical Aesthetics Ltd, London, UK
Radiological evaluation of calcium hydroxylapatite implantation to correct volume loss in the dorsum of the hand. Amir Moradi, MD – Private Practice, Vista, CA, US
CaHA microspheres: Contact with fibroblasts and amount of spheres are key factors for collagen stimulation. Bartosch Nowag – Merz Pharmaceuticals GmbH, Frankfurt, Germany
Calcium hydroxylapatite: A safety review. Jonathan A. Kadouch, MD, PhD – ReSculpt Clinic, Amsterdam, The Netherlands

Ultherapy ^®

Upper Body Lifting and Tightening with Calcium Hydroxylapatite and Microfocused Ultrasound with Visualization. Jani van Loghem, MD – Falck Clinic, Amsterdam, The Netherlands
Differentiation of microfocused ultrasound with visualization treatment using a customized management protocol of see-plan-treat. Julia Sevi, MBChB – Aesthetic Health, Leeds, UK
Microfocused Ultrasound with Visualization: Treatment Plans and Comfort Management in Real-World Practice. Amanda K. Doyle, MD – Russak Dermatology, New York, NY, US

Cellfina ^®

Multicenter Pivotal Study of the Safety and Effectiveness of a Tissue Stabilized-Guided Subcision Procedure for the Treatment of Cellulite - 5 Year Update. Michael S. Kaminer, SkinCare Physicians, Chestnut Hill, MA, US

About Merz

Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately-held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetics products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20190404005258/en/

Contact:

Media Contact Merz Pharma GmbH & Co. KGaA Global Communications Mariana Smith Bourland Phone: +49 151 4249 1466 Email: mariana.smith@merz.com http://www.merzaesthetics.com

Link:

ClickThru

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nakiki SE: Nakiki SE Evaluates Corporate Bond Offering for Strategic Bitcoin Investment27.8.2025 18:51:00 CEST | Press release

Nakiki SE is currently evaluating the issuance of a corporate bond with a target volume in the mid–single-digit million-euro range. As part of a pre-market sounding process, the Management Board is assessing interest from professional investors. The proceeds of the issuance are intended primarily for the acquisition of Bitcoin. Language: English Company: Nakiki SE Hanauer Landstr. 204 60314 Frankfurt on the Main Germany E-mail: info@nakikifinance.com Internet: https://nakikifinance.com/ ISIN: DE000WNDL300, DE000WNDL318 WKN: WNDL30, WNDL31 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange View source version on businesswire.com: https://www.businesswire.com/news/home/20250827593566/en/

Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm27.8.2025 17:30:00 CEST | Press release

AI-driven automation leader receives the highest scores possible in ten criteria Boomi™, the leader in AI-driven automation, today announced it has been named a Leader in The Forrester Wave™: Integration Platform As A Service, Q3 2025. The report evaluated the 10 most significant iPaaS vendors, and Boomi achieved the highest score in thestrategy category among all evaluated providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826324359/en/ Boomi Named a Leader and Secures Top Score in Strategy Category in Latest iPaaS Report by Independent Research Firm The report states that Boomi has reoriented with an “intense focus on AI and APIs,” “receives strong feedback from its partners,” and maintains “clear investment priorities.” Reference customers were impressed by the company’s level of investment in the product and its vision for the future, and look forward to seeing Boomi deliver on its AI roadmap. “We’re honored to

Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences27.8.2025 16:00:00 CEST | Press release

Altasciences, a fully integrated CRO/CDMO offering comprehensive early-phase drug development solutions, is pleased to announce a strategic collaboration with Evidence Matters, a pioneer in clinical trial data science and document engineering. This partnership combines Altasciences' real-world drug development expertise with Evidence Matters' innovative, patent-pending Text Engineering technology—a breakthrough that delivers near-deterministic accuracy in regulatory writing by reducing variability and improving the quality, consistency, and speed of documentation. Evidence Matters’ RegulatoryFlow platform (“RegFlow”) and specialized services unify clinical data and documents, simplify workflows, and accelerate the work of key life sciences professionals, from medical writers to regulatory specialists. “We are excited to work alongside Evidence Matters to co-develop technology that directly enhances the quality and efficiency of regulatory writing,” said Nicole Maciolek, Vice President,

Veridas Named a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification27.8.2025 14:34:00 CEST | Press release

Recognised in Gartner research as a leading global IDV vendor, with a fully proprietary stack, certified accessibility, and a vision for reusable, user-centric digital identity. Veridas, a global identity company, has been recognized as a Visionary in the 2025 Gartner® Magic Quadrant™ for Identity Verification, reinforcing its position among the top global IDV vendors. Founded in 2017 and operating globally, Veridas enters the report as one of the fastest-growing companies in the market. Gartner defines Visionaries as vendors that understand where the market is going or have a vision for changing market rules. This positioning validates Veridas’ long-term strategy and highlights its leadership in innovation, ethical design, and user-centric digital identity. At the core of Veridas’ approach is its 100% proprietary technology stack, covering facial biometrics, voice authentication, document verification, age validation, physical access control, and its ID Wallet. By developing all core

Boyd Launches Rack Emulator to Validate Liquid Cooling System Performance for AI Infrastructure27.8.2025 14:05:00 CEST | Press release

Boyd Enables Faster Testing and Validation of Direct-to-Chip Liquid Cooling Loops, Coolant Distribution Units, and Facility Cooling Systems with Boyd’s Rack Emulator Boyd, whose chip-to-ambient liquid cooling technologies make it easier for data center owners and operators to implement new AI infrastructure, announced it launched a new thermal testing tool to help end clients more safely and efficiently deploy liquid cooled data centers and improve time to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250827491684/en/ Boyd's new Rack Emulator validates liquid cooling system performance in AI data centers, helping clients more safely and efficiently deploy liquid cooled data centers with improved speed of deployment. Boyd's Rack Emulator simulates the pressure drop and heat dissipation of a rack and uses automation to test coolant distribution units (CDUs) and facility cooling systems to validate thermal performance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom